Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases.

Abstract

BACKGROUND:

Patients with rheumatoid arthritis (RA) and other chronic inflammatory rheumatic disorders have increased risk of cardiovascular disease (CVD) and venous thromboembolism (VTE) compared with the general population. Moreover, recent data have raised concerns around a possible increased risk of major CV events (MACE) and VTE in patients treated with JAK inhibitors (JAKi). In October 2022, the PRAC has recommended measures to minimize the risk of serious side effects, including CV conditions and VTE, associated with all approved in chronic inflammatory diseases.

OBJECTIVE:

To provide an adequate and feasible strategy to evaluate, at the individual level, the risk of CVD and VTE in patients with chronic inflammatory rheumatic diseases.

METHODS:

A multidisciplinary steering committee comprised 11 members including rheumatologists, a cardiologist, a hematologist expert in thrombophilia and fellows. Systematic literature searches were performed and evidence was categorized according to standard guidelines. The evidence was discussed and summarized by the experts in the course of a consensus finding and voting process.

RESULTS:

Three overarching principles were defined. First, there is a higher risk of MACE and VTE in patients with chronic inflammatory rheumatic diseases compared with the general population. Second, the rheumatologist has a central role in the evaluation of the risk of CVD and VTE in patient with chronic inflammatory rheumatic diseases. Third, the risk of MACE and VTE should be regularly assessed in patients with chronic inflammatory rheumatic diseases, particularly before initiating targeted therapies. Eleven recommendations were defined to prevent potentially life-threatening complications of CVD and VTE in patients with chronic inflammatory rheumatic diseases, providing practical assessment of CVD and VTE before considering the prescription of targeted therapies, and especially JAKi.

CONCLUSION:

These practical recommendations based on expert opinion and scientific evidence provide consensus for the prevention and the assessment of CVD and VTE.

• Authors: Jérôme Avouac, Olivier Fogel, Sophie Hecquet, Claire Daien, Ismail Elalamy, Fabien Picard, Clément Prati, Jean Hugues Salmon, Marie-Elise Truchetet, Jérémie Sellam, Anna Molto, behalf of the French Society of Rheumatology
• Journal: Joint bone spine (Joint Bone Spine) Vol. 90 Issue 5 Pg. 105592 (09 2023) ISSN: 1778-7254 [Electronic] France
• PMID: 37201575 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Topics

• Humans
• Arthritis, Rheumatoid (complications)
• Cardiovascular Diseases (epidemiology, etiology, prevention & control)
• Rheumatic Diseases (complications, drug therapy)
• Risk Factors
• Venous Thromboembolism (epidemiology, etiology, prevention & control)
• Practice Guidelines as Topic